Official Title
Expanded Access to Telisotuzumab Vedotin
Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available
Individual Patients
Non-small Cell Lung Cancer (NSCLC)

Drug: Telisotuzumab vedotin
Intravenous Infusion
Other Name: ABBV-399

Eligibility Criteria

Inclusion Criteria: - The participant must not be eligible for a telisotuzumab vedotin clinical trial.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Contacts

ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com

AbbVie Inc.
Study Director
AbbVie

NCT Number
Keywords
Non-Small Cell Lung Cancer (NSCLC)
Telisotuzumab vedotin
ABBV-399
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
MeSH Terms
Carcinoma, Non-Small-Cell Lung
Intervention Name
Telisotuzumab vedotin